Completed PHASE1 INTERVENTIONAL 1-arm NCT02103894

Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects

Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Clinically Diagnosed Tauopathies in Comparison to Healthy Subjects

Sponsor: Institute for Neurodegenerative Disorders

Conditions Alzheimer's Disease (AD) Chronic Traumatic Encephalopathy (CTE) Frontal Temporal Dementia (FTD) Parkinson's Disease (PD) Pick's Disease Progressive Supranuclear Palsy (PSP) Tauopathies

Interventions [18F]T807 ([18F]MNI-777)

Updated 6 times since 2017 Last updated: Dec 15, 2016 Started: Feb 28, 2014 Primary completion: Aug 31, 2016 Completion: Sep 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Alzheimer's Disease (AD) and Chronic Traumatic Encephalopathy (CTE) and is currently completed. Institute for Neurodegenerative Disorders leads this study, which shows 6 recorded versions since 2014 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Feb 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Institute for Neurodegenerative Disorders
Molecular NeuroImaging

Data source: Molecular NeuroImaging

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New Haven, United States